The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients

Last updated: January 30, 2024
Sponsor: Huazhong University of Science and Technology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bladder Cancer

Urothelial Carcinoma

Urothelial Cancer

Treatment

This was a retrospective study and no patient intervention was performed

Clinical Study ID

NCT06245759
TJIRB20230888
  • Ages > 18
  • All Genders

Study Summary

Based on large sample size studies at home and abroad, the prognosis of patients with non-muscular invasive bladder cancer in different sites undergoing transurethral bladder tumor resection was determined, providing important guidance for subsequent clinical treatment and surgical instrument development.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Initially diagnosed with non-muscular invasive bladder cancer (NMIBC) who underwentTURBT or partial cystectomy.
  2. The follow-up data of the patients were complete.
  3. The tumor location information were complete.

Exclusion

Exclusion Criteria:

  1. Patients with unknown survival time or missing tumor location information wereexcluded.
  2. Exclude patients with missing pathological results.
  3. Exclude patients who have had TURBT before.

Study Design

Total Participants: 120000
Treatment Group(s): 1
Primary Treatment: This was a retrospective study and no patient intervention was performed
Phase:
Study Start date:
August 31, 2023
Estimated Completion Date:
December 31, 2024

Study Description

Background Most bladder cancers are non-muscle invasive bladder cancer (NMIBC), and transurethral resection of bladder tumors (TURBT) is the standard treatment. However, postoperative recurrence poses a challenge, and the influence of bladder tumor location on prognosis is unclear. This study aims to investigate how tumor location affects NMIBC patients' prognosis undergoing TURBT, and seeks optimal surgical approaches.

Methods Conducted a multicenter study, including Chinese NMIBC data from 15 hospitals (1996-2019) and SEER 17 registries (2000-2020). Analyzed patients initially diagnosed with NMIBC undergoing TURBT or partial cystectomy, excluding cases with lost follow-up or missing data. Studied overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Employed Kaplan-Meier, Cox regression, and propensity score matching to explore the association between tumor location and prognosis. Stratified populations were analyzed to minimize bias.

Findings This study, involving 118,477 NMIBC patients, highlighted tumor location as a crucial factor impacting post-TURBT prognosis. Anterior wall and dome tumors independently predicted adverse outcomes in both cohorts. For anterior wall tumors, Chinese cohort showed OS HR 4.35, p < 0.0001; RFS HR 2.21, p < 0.0001; SEER OS HR 1.10, p = 0.0001; DSS HR 1.13, p = 0.0183. Dome tumors displayed similar trends (Chinese NMIBC cohort OS HR 7.91, p < 0.0001; RFS HR 2.12, p < 0.0001; SEER OS HR 1.05, p = 0.0087; DSS HR 1.14, p = 0.0006). Partial cystectomy significantly improved dome tumor survival compared to standard TURBT (p < 0.01).

Interpretation This study reveal that NMIBC tumor location significantly influences TURBT treatment outcomes. Specifically, tumors in the anterior wall and bladder dome have worse post-TURBT prognosis. Compared to TURBT, partial cystectomy improves prognosis for bladder dome tumors. This study guides personalized treatment and prognosis management for NMIBC patients.

Connect with a study center

  • Ke Chen

    Wuhan, Hubei 430022
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.